Recent Significant Events: 05/14/15- StemCells, Inc. (the "Company") issued a press release announcing top-line positive results from its Phase I/II trial in thoracic
spinal cord injury.
The Company’s international, open-label, Phase I/II trial evaluated both safety and preliminary efficacy of its proprietary HuCNS-SC human
neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve patients who had suffered injury to the thoracic cord
and were in the early chronic stage of recovery. The analysis of the study demonstrated that the surgical transplantation technique and cell dose
were safe and well tolerated by all patients. In addition to safety, analysis of the twelve-month data revealed sustained improvements in sensory
function that emerged consistently around three months after transplantation and persisted until the end of the study.
In March 2015, Ian Massey, D. Phil., has joined our executive team as President and Chief Operating Officer. In this new role,
Dr. Massey has direct responsibility for all aspects of the Company’s research and development, manufacturing, regulatory affairs, and quality
assurance activities. He reports to Martin McGlynn, the Company’s Chief Executive Officer.
In April 2015, we completed transplanting the six patients comprising the first cohort of our Phase II Pathway Study. The first cohort is
an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a
single-blind arm in 40 patients that will assess efficacy of our proprietary HuCNS-SC platform technology for the treatment of cervical spinal
cord injury.
In April 2015, we raised gross proceeds of approximately $25 million through a public offering of 35,715,000 Units.
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
